


Claims

1. A compound according to Formula (I)



(I)

or a pharmaceutically acceptable salt thereof, wherein

X is N or CH;

Y is CH or N;

A is CH₂, O or N(H) when Y is CH, or

A is CH₂ when Y is N;

B is O or CR⁷R⁸;

Z¹ is CR⁴ or N;

R is hydrogen, C₁-C₄alkyl, monofluoromethyl, difluoromethyl or trifluoromethyl;

R¹ is hydrogen, halogen, C₁-C₄alkyl or trifluoromethyl

R² is piperidinyl which is N-substituted with C₁-C₄alkyl, C₃-C₆cycloalkyl, haloC₁-C₄alkyl, C(O)C₁-C₄alkyl, S(O)₂C₁-C₄alkyl, C(O)C₃-C₆cycloalkyl, C(O)haloC₁-C₄alkyl, C(O)C₁-C₄alkoxy, C(O)C₁-C₄alkenoxy, heteroaryl or CO(O)₂benzyl, wherein each cycloalkyl is optionally substituted by hydroxy and each alkyl or alkoxy is optionally substituted by hydroxyl, C₁-C₄alkoxy or C₃-C₆cycloalkyl and wherein each heteroaryl has 5 or 6 ring atoms, 1, 2 or 3 ring heteroatoms independently selected from N, O and S and is optionally substituted with 1 or 2 C₁-C₄alkyl substituents.

R³ is hydrogen, halogen or C₁-C₄alkyl; or

R² and R³, taken in combination, form a 5 or 6 member fused saturated azacyclic ring optionally substituted with benzyl or 5 or 6 member heteroarylmethyl, which heteroaryl has 1 or 2 ring heteroatoms independently selected from N, O and S;

R⁴ is hydrogen or C₁-C₄alkyl;

R^5 is hydrogen, halogen, C_1 - C_4 alkyl or C_3 - C_6 cycloalkyl;


R^7 is hydrogen or C_1 - C_4 alkyl; or

R^7 and R^9 , taken in combination with the ring atoms to which they are attached form a carbon-carbon double bond;

R^8 is hydrogen or C_1 - C_4 alkyl; and

R^9 is hydrogen or C_1 - C_4 alkyl.

2. A compound according to Formula (Ia)



or a pharmaceutically acceptable salt thereof, wherein

X is N or CH;

Y is CH or N;

A is CH_2 , O or N(H) when Y is CH, or

A is CH_2 when Y is N;

R is hydrogen, C_1 - C_4 alkyl or trifluoromethyl;

R^1 is hydrogen, halogen or C_1 - C_4 alkyl;

R^2 is piperidinyl which is N-substituted with C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, halo C_1 - C_4 alkyl, $C(O)C_1$ - C_4 alkyl, $C(O)C_3$ - C_6 cycloalkyl, $C(O)$ halo C_1 - C_4 alkyl or $C(O)C_1$ - C_4 alkoxy;

R^3 is hydrogen or C_1 - C_4 alkyl; or


R^2 and R^3 , taken in combination, form a 5 or 6 member fused saturated azacyclic ring optionally substituted with benzyl or 5 or 6 member heteroarylmethyl, which heteroaryl has 1 or 2 ring heteroatoms independently selected from N, O and S;

R^4 is hydrogen or C_1 - C_4 alkyl and

R^5 is hydrogen, halogen, C_1 - C_4 alkyl or C_3 - C_6 cycloalkyl.

3. The compound of claim 1 or claim 2, wherein Y is CH and A is N(H).

4. The compound of any one of claims 1 to 3, wherein R^2 is N-substituted piperidin-4-yl wherein the N-substituent is 2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl.
5. The compound of any one of claims 1 to 4, wherein R^1 is methyl; and R^3 and R^4 are hydrogen.
6. The compound of any one of claims 1 to 5, wherein R is methyl or ethyl.
7. The compound of claim 1 or claim 2, wherein the compound is a compound according to Formula (II):



(II)

wherein

A is O, CH₂ or NH;

R is methyl, ethyl or trifluoromethyl;

R^6 is 2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl.

8. The compound of claim 1 which is 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid; or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 which is (-)-(R)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid; or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 which is (+)-(S)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid; or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1 which is (+)-(S)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid in sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc and copper salt form.

12. The compound of claim 1 which is (+)-(S)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid in isopropylamine, benzathine, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine salt form.
13. A pharmaceutical composition comprising a compound of any one of claims 1 to 12, or a salt thereof, and a pharmaceutically acceptable excipient.